Related Experiment Video
Updated: Mar 13, 2026

In Vivo Mouse Model of Spinal Implant Infection
Published on: June 23, 2020
Suppressive antibiotic therapy for spinal hardware infection: a retrospective cohort study
Adil Choudhry1, James B Doub2, Uzoamaka A Eke3
1Division of Infectious Diseases, University of Maryland Medical School, Baltimore, MD, USA.
Background:
Spinal hardware infection (SHI) is one of the most devastating complications of spine surgery with challenging and undefined antibiotic treatment modalities.
Methods:
Retrospective cohort study of patients ≥ 18 years of age who underwent surgery for the treatment of SHI at a university center between 1st January2015, to 1st January 2020. The aim was to determine the appropriate duration of suppressive antibiotic therapy (SAT) for SHI based on recurrent infection rate on SAT, rate of adverse drug reaction (ADR) from SAT, and rate of antibiotic resistance to SAT in patients with SHI.
Results:
The median age of the 82 patients who met eligibility criteria for the study was 61 years (53-73), 55% were female, 60% had multimorbidity and 54% had early infection. Staphylococcus aureus was the most common cultured organism (45%) and 29 (35%) of patients had bacteremia. 54 (66%) received SAT with a median duration of 52 weeks (12 to 191 weeks). 12 (15%) had recurrence, while 8 (10%) developed recurrence on SAT. Neither SAT nor SAT duration (< 24 weeks, 24-52 or > 52 weeks) was associated with recurrence in early or late infection, regardless of hardware status. There was a non-significant higher recurrence rate with partial hardware revision, 7.3% (OR 6.30 [0.70-57.07]) and full hardware retention, 6.1% (OR 3.62 [0.39-33.30]) compared to complete hardware removal, (1.2%). ADR occurred in 6 (11%) of patients on SAT and in 11 (14%) of patents while on intravenous therapy, with no significant difference (mid-p exact 95% CI [0.32-1.80], p = 0.82). Only one case of drug resistance occurred with SAT.
Conclusion:
In patients who underwent surgery for SHI, neither the use of SAT nor SAT duration had any impact on recurrence of SHI regardless of SHI onset or hardware status. The rate of ADR with SAT was comparable to ADR with intravenous antibiotics and the rate of development of drug resistance was low. A randomized control trial is urgently needed to determine the role of SAT and its optimal application in the treatment of SHI.
Clinical Trial Number:
Not applicable.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Endocarditis III: Medical Management
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Tonsillitis II: Management
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

